Taysha halts gene therapy development amidst FDA controversy and partnership dissolution

Taysha Gene Therapies has halted the development of a neurodegenerative therapy for giant axonal neuropathy (GAN) after the FDA insisted on a randomized, placebo-controlled trial, which the company deemed potentially impossible. This highlights the challenges of bringing medicines targeting ultra-rare conditions to market.